MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Home・Listă Acțiuni・Axsome Therapeutics Inc

Axsome Therapeutics Inc

Închisă

SectorSănătate

119.75 1.31

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

116.11

Maxim

120.54

Indicatori cheie
By Trading Economics
Venit	11M -48M
Vânzări	29M 150M
Marjă de profit	-31.973
Angajați	846
EBITDA	20M -37M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+44.34% upside

Dividende
By Dow Jones
Următoarele câștiguri	11 nov. 2025

Statistici piață
By TradingEconomics
Capitalizare de piață	562M 5.9B
Deschiderea anterioară	118.44
Închiderea anterioară	119.75

Sentimentul știrilor

By Acuity

14%

86%

18 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

107.24 / 112.29 Suport & Rezistență

Axsome Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 oct. 2025, 23:30 UTC

Acțiuni populare

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 oct. 2025, 21:21 UTC

Câștiguri

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 oct. 2025, 00:00 UTC

Achiziții, Fuziuni, Preluări

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 oct. 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 oct. 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 oct. 2025, 23:29 UTC

Achiziții, Fuziuni, Preluări

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 oct. 2025, 23:29 UTC

Achiziții, Fuziuni, Preluări

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 oct. 2025, 23:29 UTC

Achiziții, Fuziuni, Preluări

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 oct. 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 oct. 2025, 22:54 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Scales's JV Buyout Lauded by Bull -- Market Talk

2 oct. 2025, 22:54 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Global Forex and Fixed Income Roundup: Market Talk

2 oct. 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 oct. 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 oct. 2025, 21:17 UTC

Achiziții, Fuziuni, Preluări

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 oct. 2025, 20:50 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Energy & Utilities Roundup: Market Talk

2 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 oct. 2025, 20:49 UTC

Achiziții, Fuziuni, Preluări

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 oct. 2025, 20:00 UTC

Achiziții, Fuziuni, Preluări

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 oct. 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 oct. 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 oct. 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 oct. 2025, 18:46 UTC

Achiziții, Fuziuni, Preluări

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 oct. 2025, 18:46 UTC

Achiziții, Fuziuni, Preluări

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 oct. 2025, 18:46 UTC

Achiziții, Fuziuni, Preluări

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 oct. 2025, 18:45 UTC

Achiziții, Fuziuni, Preluări

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 oct. 2025, 18:45 UTC

Achiziții, Fuziuni, Preluări

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 oct. 2025, 18:44 UTC

Achiziții, Fuziuni, Preluări

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 oct. 2025, 18:44 UTC

Achiziții, Fuziuni, Preluări

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 oct. 2025, 18:44 UTC

Achiziții, Fuziuni, Preluări

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 oct. 2025, 18:43 UTC

Achiziții, Fuziuni, Preluări

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Comparație

Modificare preț

Axsome Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

44.34% sus

Prognoză pe 12 luni

Medie 171.14 USD 44.34%

Maxim 200 USD

Minim 144 USD

În baza a 16 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAxsome Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

16 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 16 analiști care au acordat evaluări ale acțiunilor Axsome Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

107.24 / 112.29Suport & Rezistență

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bullish.

Sentiment

By Acuity

18 / 371 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.